# Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

> **NCT02203526** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 68 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Isavuconazole
- **DRUG:** TEDDI
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** TEDD
- **DRUG:** Ibrutinib (Arms 2, 3 and 4)
- **DRUG:** Methotrexate
- **DRUG:** Ibrutinib (Arm 1 - Closed with Amendment G)
- **DRUG:** Ibrutinib (Arm 4)

## Key facts

- **NCT ID:** NCT02203526
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-08-14
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203526, "Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02203526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*